Wells Fargo
ALXN

Wells Fargo’s Alexion Pharmaceuticals ALXN Stock Holding History

Wells Fargo’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-904,290
Closed -$166M – 7938
2021
Q2 		$166M Buy
904,290
+338,049
+60% +$58M 0.04% 451
2021
Q1 		$86.6M Sell
566,241
-307,223
-35% -$47.5M 0.02% 747
2020
Q4 		$136M Sell
873,464
-51,200
-6% -$6.58M 0.03% 507
2020
Q3 		$106M Sell
924,664
-75,114
-8% -$8.1M 0.03% 542
2020
Q2 		$112M Sell
999,778
-339,191
-25% -$36M 0.03% 497
2020
Q1 		$120M Sell
1,338,969
-316,222
-19% -$31M 0.04% 406
2019
Q4 		$179M Sell
1,655,191
-273,588
-14% -$29.3M 0.05% 382
2019
Q3 		$189M Sell
1,928,779
-526,693
-21% -$59.4M 0.05% 360
2019
Q2 		$322M Buy
2,455,472
+366,523
+18% +$47.2M 0.09% 212
2019
Q1 		$282M Buy
2,088,949
+319,172
+18% +$39.7M 0.08% 228
2018
Q4 		$172M Sell
1,769,777
-22,543
-1% -$2.66M 0.06% 321
2018
Q3 		$249M Buy
1,792,320
+306,585
+21% +$38.5M 0.07% 282
2018
Q2 		$184M Buy
1,485,735
+178,018
+14% +$20.8M 0.05% 348
2018
Q1 		$146M Buy
1,307,717
+65,994
+5% +$7.89M 0.04% 434
2017
Q4 		$148M Sell
1,241,723
-316,808
-20% -$38.6M 0.04% 428
2017
Q3 		$219M Buy
1,558,531
+383,713
+33% +$52.1M 0.07% 303
2017
Q2 		$143M Sell
1,174,818
-21,897
-2% -$2.55M 0.05% 409
2017
Q1 		$145M Sell
1,196,715
-685,315
-36% -$88.4M 0.05% 404
2016
Q4 		$230M Sell
1,882,030
-1,543,010
-45% -$189M 0.08% 251
2016
Q3 		$420M Sell
3,425,040
-221,639
-6% -$28.5M 0.15% 145
2016
Q2 		$426M Sell
3,646,679
-975,673
-21% -$138M 0.17% 141
2016
Q1 		$644M Sell
4,622,352
-1,353,659
-23% -$199M 0.26% 85
2015
Q4 		$1.14B Sell
5,976,011
-259,806
-4% -$45.4M 0.45% 31
2015
Q3 		$975M Buy
6,235,817
+838,201
+16% +$153M 0.41% 36
2015
Q2 		$976M Buy
5,397,616
+1,113,561
+26% +$192M 0.38% 38
2015
Q1 		$742M Sell
4,284,055
-112,316
-3% -$20.3M 0.29% 69
2014
Q4 		$813M Sell
4,396,371
-105,646
-2% -$19.6M 0.32% 59
2014
Q3 		$747M Sell
4,502,017
-731,184
-14% -$120M 0.31% 57
2014
Q2 		$818M Sell
5,233,201
-797,511
-13% -$126M 0.34% 46
2014
Q1 		$917M Sell
6,030,712
-1,669,284
-22% -$265M 0.39% 37
2013
Q4 		$1.02B Buy
7,699,996
+1,741,276
+29% +$209M 0.44% 32
2013
Q3 		$692M Buy
5,958,720
+17,528
+0.3% +$1.92M 0.33% 55
2013
Q2 		$548M Buy
+5,941,192
New +$573M 0.28% 75

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Wells Fargo's ALXN Position: Q3 2021 in Review

Wells Fargo sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 904,290 shares — an estimated $166M sold.

Wells Fargo first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $1.14B in Q4 2015. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Wells Fargo reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Wells Fargo sold 904,290 Alexion Pharmaceuticals shares in Q3 2021, an estimated $166M.
  • Wells Fargo first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Wells Fargo's Alexion Pharmaceuticals position peaked at $1.14B in Q4 2015.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Wells Fargo's 13F filing for Q3 2021, filed 15 Nov 2021.